Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2018

View Archived Issues

T-cell bispecfic antibody against p95HER2 mediates on-target killing of tumor cells

Pegfilgrastim biosimilar INTP-5 bioequivalent to Neulasta

Pancreatic islet cells express "innate immune" protein

Zafgen presents interim analysis results from phase II study of ZGN-1061

Acurx and WuXi collaborate to advance the development of first-in-class antibiotics

Vedolizumab may help eliminate HIV infection by attenuating lymphoid aggregates

Zika virus persists in serum for over 7 months after disease onset

Resistance drives convergence onto SCNC

Innate immune inhibition fights glaucoma

Pulmocide presents phase I safety and pharmacokinetic data for PC-786

JNJ-8678 demonstrates early antiviral effect in RSV-infected infants

Phase II data presented for serlopitant as treatment for refractory chronic cough

Green Cross initiates phase II study of high-dose quadrivalent influenza vaccine GC-3114

Genzyme recruits patients at risk of rapidly progressive ADPKD in phase II/III study of GZ-402671

Amicus and University of Pennsylvania establish gene therapy collaboration

Metabolic control seen in high-fat diet-fed mice by a novel hybrid peptide

Phase III study of Otezla in moderate to severe scalp psoriasis meets primary endpoint

Exelixis initiates phase III study of cabozantinib in radioiodine-refractory DTC

Affimed places AFM-11 program on clinical hold

VBI-1501 demonstrates safety and immunogenicity in first-in-human study

FDA issues complete response letter for Acacia's Barhemsys

FDA approves IND for first-in-human study of Coordination's CPI-100

Nosopharm develops synthetic odilorhabdins with good safety and potent antibacterial activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...